ChemSpider 7981825
Chemical and physical data
Formula C25H25Cl2N3O
Molar mass 454.40 g·mol−1
3D model (Jmol) Interactive image

MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).[2][3][4] It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,[4][5][6] and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors.[4][6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.[3]

See also


  1. Kato, Tadafumi; Saijo, Takeaki; Maeda, Jun; Okauchi, Takashi; Maeda, Jun-ichi; Morio, Yasunori; Kuwahara, Yasuhiro; Suzuki, Masayuki; Goto, Nobuharu; Fukumura, Toshimitsu; Suhara, Tetsuya; Higuchi, Makoto (2012). "Presynaptic Selectivity of a Ligand for Serotonin 1A Receptors Revealed by In Vivo PET Assays of Rat Brain". PLoS ONE. 7 (8): e42589. doi:10.1371/journal.pone.0042589. ISSN 1932-6203.
  2. "Minerva Neuroscience". Retrieved 2015-05-19.
  3. 1 2 Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates". GlobalNewswire. Retrieved 2015-05-19.
  4. 1 2 3 Minerva Neurosciences. "Investor Presentation March 2015" (PDF). Retrieved 2015-05-19.
  5. "Company Profile for Minerva Neurosciences Inc.". Reuters. Retrieved 2015-05-19.
  6. 1 2 Don Dion (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved 2015-05-19.

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.